EPHA2 and pancreatic neoplasm: Of these, EPHA2 is particularly well characterized in PDAC with other groups recently presenting evidence of EPHA2-mediated drug resistance in pancreatic cancer cells [29] and proposing EPHA2 as a potential biomarker or therapeutic target in pancreatic cancer [29,40].